Kezar Life Sciences (KZR) Debt to Equity (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Debt to Equity for 5 consecutive years, with $0.08 as the latest value for Q3 2025.
- Quarterly Debt to Equity rose 4.74% to $0.08 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $0.08 through Sep 2025, up 4.74% year-over-year, with the annual reading at $0.09 for FY2024, 64.56% up from the prior year.
- Debt to Equity hit $0.08 in Q3 2025 for Kezar Life Sciences, down from $0.09 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.09 in Q4 2024 to a low of $0.03 in Q2 2022.
- Historically, Debt to Equity has averaged $0.06 across 5 years, with a median of $0.05 in 2021.
- Biggest five-year swings in Debt to Equity: dropped 25.44% in 2022 and later soared 65.19% in 2024.
- Year by year, Debt to Equity stood at $0.05 in 2021, then decreased by 25.44% to $0.04 in 2022, then skyrocketed by 47.32% to $0.05 in 2023, then soared by 64.56% to $0.09 in 2024, then fell by 9.23% to $0.08 in 2025.
- Business Quant data shows Debt to Equity for KZR at $0.08 in Q3 2025, $0.09 in Q2 2025, and $0.09 in Q1 2025.